Loading...
XOSLNYKD
Market cap78mUSD
Dec 23, Last price  
3.02NOK
1D
4.57%
1Q
-40.78%
IPO
-95.05%
Name

Nykode Therapeutics ASA

Chart & Performance

D1W1MN
XOSL:NYKD chart
P/E
P/S
6.09
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
1.22%
Rev. gr., 5y
151.20%
Revenues
13m
-81.29%
243,149486,180129,00002,023,901,420292,031,29468,960,87612,902,000
Net income
-35m
L-91.45%
-16,220,187-31,370,621-63,793,000-120,556,3591,409,896,797-80,946,400-411,215,782-35,154,000
CFO
-97m
L-41.07%
-62,783,000-92,195,3341,696,641,26711,711,174-163,964,873-96,624,000
Earnings
Feb 26, 2025

Profile

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
IPO date
Jan 27, 2020
Employees
Domiciled in
NO
Incorporated in
NO

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
12,902
-81.29%
68,961
-76.39%
292,031
-85.57%
Cost of revenue
35,636
507,249
345,910
Unusual Expense (Income)
NOPBT
(22,734)
(438,288)
(53,878)
NOPBT Margin
Operating Taxes
(8,932)
(79,274)
(14,652)
Tax Rate
NOPAT
(13,802)
(359,014)
(39,226)
Net income
(35,154)
-91.45%
(411,216)
408.01%
(80,946)
-105.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
45,697
17,288
182,142
BB yield
-0.71%
-0.21%
-0.79%
Debt
Debt current
1,457
11,299
11,905
Long-term debt
9,995
47,365
57,143
Deferred revenue
38,635
45,503
Other long-term liabilities
2
296
43,342
Net debt
(150,502)
(1,974,898)
(1,949,470)
Cash flow
Cash from operating activities
(96,624)
(163,965)
11,711
CAPEX
(1,902)
(25,735)
(7,498)
Cash from investing activities
7,040
70,875
90,138
Cash from financing activities
44,589
3,781
176,321
FCF
69,522
(372,035)
(53,777)
Balance
Cash
161,954
2,033,108
2,014,100
Long term investments
453
4,418
Excess cash
161,309
2,030,114
2,003,916
Stockholders' equity
29,926
726,029
992,314
Invested Capital
147,061
874,572
825,261
ROIC
ROCE
EV
Common stock shares outstanding
300,520
290,119
286,345
Price
21.40
-23.90%
28.12
-65.15%
80.70
7.61%
Market cap
6,431,136
-21.17%
8,158,146
-64.70%
23,108,027
4.05%
EV
6,280,634
6,183,248
21,158,557
EBITDA
(20,612)
(420,846)
(47,550)
EV/EBITDA
Interest
224
241
130
Interest/NOPBT